Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth - GBI Research Reports

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth - GBI Research Reports
Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth
Published Sep 17, 2011
121 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth provides in-depth analysis of the, drivers and barriers that affect the global immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Epidemiology, revenue, and annual cost of therapy are forecast until 2017 for the key geographies as well as seven key therapeutic segments. The report also provides profiles for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -
- Annualized market data for the immunoglobulins market from 2002 to 2010, and forecast to 2017.
- Analysis of the seven key therapeutic segments. These include PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura.
- Analysis of the immunoglobulins markets in the leading geographies of the world, which include the US, the top five countries in Europe and Japan.
- Market characterization of the immunoglobulins (PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura) market, including market size, revenue analysis by the top seven geographies, annual cost of therapy, and epidemiology.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive profiling of the leading companies. The key companies studied in this report are Baxter International Inc., Biotest, Bio Products Laboratory Ltd., CSL Behring LLC, Kedrion, LFB, Octapharma, Talecris, and Grifols.
- Key M&A activities and licensing agreements between 2004 and 2011 in the global immunoglobulins market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC073MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables72
  List of Figures92
Global Immunoglobulins Market: Introduction112
  Overview111
  GBI Research Report Guidance121
Global Immunoglobulins Market: Market Overview138
  Introduction131
    Rising Demand for Immunoglobulins Attributed to New Indications141
    On-Label Uses versus Off-Label Uses in the US151
    IVIG vs. SCIG Usage151
  Revenue Forecasts for the Global Immunoglobulins Market162
  Annual Cost of Therapy181
  Immunoglobulins Market Drivers and Restraints191
    Immunoglobulins Market Drivers201
      Increasing Off-Label Uses Pushing Market for Immunoglobulins201
      Neuroimmunologic Diseases Such as CIDP, MMN and GBS are Significant Growth Drivers201
      Awareness Drives in Europe Regarding PID May Push Growth201
    Immunoglobulins Market Restraints201
      Consolidation in Plasma Fractionation Facilities Represent Significant Barriers to Entry for Smaller Players201
      Limited Market Potential201
Global Immunoglobulins Market: Geographical Landscape218
  Geographical Break-up211
    The US221
      Revenue221
      Annual Cost of Therapy231
    Top Five Countries in Europe241
      Revenue242
      Annual Cost of Therapy261
    Japan271
      Revenue271
      Annual Cost of Therapy281
Global Immunoglobulins Market: Therapeutic Landscape2958
  Primary Immunodeficiency291
    Introduction291
    Revenue302
    Annual Cost of Therapy321
    Epidemiology331
      Diseased Population341
      Treatment Seeking Population341
      Diagnosed Population351
      Treated Population351
    Current Use361
      Current Use of Immunoglobulins361
      Current Use of Other Therapies361
    Geographical Segmentation372
  Guillain-Barr Syndrome Market391
    Introduction391
    Revenue401
    Annual Cost of Therapy411
    Epidemiology421
      Diseased Population431
      Treatment Seeking Population431
      Diagnosed Population431
      Treated Population441
    Current Use441
      Current Use of Immunoglobulin441
      Current Use of Other Therapies451
    Geographical Segmentation452
  Chronic Lymphocytic Leukemia Market471
    Introduction471
    Revenue481
    Annual Cost of Therapy491
    Epidemiology501
      Diseased Population511
      Treatment Seeking Population511
      Diagnosed Population521
      Treated Population with CLL Therapeutics521
      Treated Population with IVIG531
    Current Use541
      Current Use of Immunoglobulins541
      Current Use of Other Therapies541
    Geographical Segmentation551
  Chronic Inflammatory Demyelinating Polyneuropathy Market561
    Introduction561
    Revenue571
    Annual Cost of Therapy581
    Epidemiology591
      Diseased Population601
      Treatment Seeking Population601
      Diagnosed Population601
      Treated Population601
    Current Use611
      Current Use of Immunoglobulins611
      Current Use of Other Therapies611
    Geographical Segmentation621
  Myasthenia Gravis Market631
    Introduction631
    Revenue641
    Annual Cost of Therapy651
    Epidemiology661
      Diseased Population671
      Treatment Seeking Population671
      Diagnosed Population671
      Treated Population681
    Current Use681
      Current Use of Immunoglobulins681
      Current Use of Other Therapies681
    Geographical Segmentation691
  Multifocal Motor Neuropathy Market701
    Introduction701
    Revenue711
    Annual Cost of Therapy722
    Epidemiology742
      Diseased Population761
      Treatment Seeking Population761
      Diagnosed Population761
      Treated Population771
    Current Use771
      Current Use of Immunoglobulins771
      Current Use of Other Therapies771
    Geographical Segmentation781
  Idiopathic Thrombocytopenic Purpura791
    Introduction791
    Revenue801
    Annual Cost of Therapy811
    Epidemiology821
      Diseased Population831
      Treatment Seeking Population831
      Diagnosed Population841
      Treated Population841
    Current Use of Immunoglobulins and Other Therapies851
    Geographical Segmentation852
Global Immunoglobulins Market: Pipeline Analysis872
  Research and Development Pipeline CIDP871
  Research and Development Pipeline PID871
  Research and Development Pipeline GBS881
  Research and Development Pipeline ITP881
  Research and Development Pipeline Myasthenia Gravis881
  Research and Development Pipeline Multifocal Motor Neuropathy881
  Research and Development Pipeline CLL881
Global Immunoglobulins Market: Profiles of Marketed Products8911
  Privigen891
    Overview891
    Approved Indications891
    Safety891
      Primary Humoral Immunodeficiency891
      Chronic ITP891
    Efficacy891
      Treatment of Primary Humoral Immunodeficiency891
      Treatment of Chronic ITP901
    Clinical Study Details901
  Gammagard S/D901
    Overview901
    Approved Indications901
    Safety911
    Efficacy911
      Treatment of Primary Immunodeficiency Diseases911
      Treatment of B-cell CLL911
      Treatment of ITP911
      Treatment of Kawasaki Syndrome911
  Gammagard Liquid911
    Overview911
    Approved Indications921
    Safety921
    Efficacy921
    Clinical Study Details921
  Octagam 5%921
    Overview921
    Approved Indications931
    Safety931
    Efficacy931
  Flebogamma 5%931
    Overview931
    Safety931
    Efficacy941
  Flebogamma 10%941
    Overview941
    Safety941
    Efficacy941
  Gamunex951
    Overview951
    Safety951
    Efficacy951
      Treatment of Primary Humoral Immunodeficiency by the Intravenous Route951
      Treatment of ITP961
      Treatment of CIDP961
  Gammaplex961
    Overview961
    Safety961
    Efficacy971
    Clinical Study Details971
  Vivaglobin971
    Overview971
    Safety971
    Efficacy971
  Hizentra981
    Overview981
    Safety981
    Efficacy981
  Pentaglobin981
    Overview981
    Efficacy981
    Safety991
  Tegeline991
    Overview991
    Efficacy in multifocal motor neuropathy991
    Safety in multifocal motor neuropathy991
    Efficacy in CIDP991
    Safety in CIDP991
Global Immunoglobulins Market: Competitive Landscape1009
  Market Share Analysis: Immunoglobulins1001
  Baxter International Inc.1011
    Business Description1011
    SWOT Analysis1011
  Biotest1021
    Business Description1021
    SWOT Analysis1021
  Bio Products Laboratory Ltd.1031
    Business Description1031
    SWOT Analysis1031
  CSL Behring LLC1031
    Business Description1031
    SWOT Analysis1041
  Kedrion S.p.A.1041
    Business Description1041
    SWOT Analysis1051
  LFB S.A.1051
    Business Description1051
    SWOT Analysis1051
  Octapharma AG1061
    Business Description1061
    SWOT Analysis1061
  Talecris Biotherapeutics Holdings Corp1071
    Business Description1071
    SWOT Analysis1071
  Grifols S.A.1081
    Business Description1081
    SWOT Analysis1081
Global Immunoglobulins Market: M&A and Licensing Deals Landscape1095
  Overview1093
  R&D Licensing Agreements1121
    Kedrion Signs Up With Prometic for Access to the Latter s Technologies to Manufacture Hyperimmunes in Europe1121
    WIBP Enters Into Licensing Agreement with Prometic for the Latter s PPP System to Produce Plasma-Derived Products in China1121
  Co-Development Agreements1131
    Baxter Collaborates With Halozyme Baxter for a Subcutaneous Route of Administration of GAMMAGARD LIQUID 10%1131
Global Immunoglobulins Market: Appendix1148
  Market Definitions1141
  Abbreviations1142
  Research Methodology1165
    Coverage1161
    Secondary Research1161
    Primary Research1171
    Therapeutic Landscape1171
      Epidemiology-based Forecasting1181
    Market Size by Geography1191
    Geographical Landscape1201
    Pipeline Analysis1201
    Competitive Landscape1201
    Expert Panel Validation1201

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Immunoglobulins-Market-to-2017-Off-Label-Usage-and-Treatment-of-Primary-Immunodeficiency-Diseases-and-Neurological-Disorders-Stimulate-Market-Growth-2115-255>
  
APA:
GBI Research Reports. (2011). Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Immunoglobulins-Market-to-2017-Off-Label-Usage-and-Treatment-of-Primary-Immunodeficiency-Diseases-and-Neurological-Disorders-Stimulate-Market-Growth-2115-255>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.